Genenta Science Reports Consistent Survival Metrics for TEM-GBM Study Patients.
ByAinvest
Monday, Nov 24, 2025 4:03 am ET1min read
GNTA--
Genenta Science announced an update from its TEM-GBM study in newly diagnosed glioblastoma multiforme patients. As of November 21, 2025, 25 patients have been treated with Temferon, with key survival metrics remaining consistent. 44% of patients have reached 18-month survival, compared to 38% reported in April, and the two-year survival rate is 29%. Median overall survival remains at 17 months.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet